Romain Clément is the CEO of ArcaScience, a healthtech company founded in 2018 whose AI platform is the very first to automate benefit-risk assessment, the decision at the heart of every drug approval. By reading the full evidence base behind a molecule and structuring it the way regulators require, ArcaScience turns months of manual synthesis into a living, source-linked analysis, helping sponsors accelerate R&D, strengthen treatment safety, and better target patients. He also teaches at Paris I Panthéon-Sorbonne, where he lectures on philosophy contextualized by the industrialization of AI, data pipelines, and the impact of evidence-driven decision-making.